Ebola Exposure Qu	estionnaire for Passengers on Other Commercial			
Directions: Please fax comple	Conveyances ed form to Ebola Airline Investigation at fax # 404.718.2158 after both initial interview and completion of final disposition.			
***Note: If contact develops a 1 770.488.7100.	ever ≥100.4° F or other symptoms of Ebola, immediately call EOC at			
Date of initial interview:/	/Interviewed by:			
Interviewer's Agency:	Interviewer's Phone Number:			
Interviewer's Email:				
Passenger Information:				
1. First Name:	Last Name:			
Date of Birth:	Sex:			
Country of Citizenship:	Country of Residence:			
What are interviewee's travel plans through 21 days after potential exposure?:				
				City:
Phone numbers for next 21 c	ays: Home: Cell:			
Work:	-			
What commercial conveyance was the interviewee on? : Provide complete information- includ				
conveyance, date, origination city/state/country and destination city/state/country				
Type of commercial conveya	ce: Date:			
Origination city/state/country/bus or train stop: Destination city/state/country/bus or train stop:				
				Other information (e.g., bus number):
Location on commercial conv	eyance (e.g., where were you seated on bus/train or located on ship):			

Page 1 of 6 Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the cell of the second se searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB Control Number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA 0920-0900.

	Did interviewee move to a different seat/location? Yes No					
	If yes, which seat/location did interviewee move to?					
Document length of time in each seat/location:						
2.	Did interviewee have any interactions with sick passengers from this commercial conveyance?					
	If yes, describe this event including description of the ill passenger or their identity if known, location of					
the event, degree of contact (talking, touching, etc.) and length of time:						
3.	Did interviewee have direct contact with blood or other body fluids (including but not limited to feces,					
saliva, sweat, urine, and vomit) of any passengers during the transportation mentioned above?						
Yes No (If no, skip to question 4) If yes, describe the contact including location on the bus/train/ship of the body fluid and any other individuals involved: If yes, with which body fluids did interviewee come into contact? (Check all that apply)						
					Tears Saliva Respiratory secretions (cough and sneeze droplets)	
					Vomit Urine Blood Feces Sweat	
	If yes, did these fluids come in contact with the interviewee's? (Read below and check all that apply):					
	Intact skin					
	Broken skin (fresh cut or scratch which bled within 24 hours before the contact; burn or					
	abrasion that had not dried)					
	Mucous membrane contact (eyes, nose or mouth)					
	Other (Specify):					
4.	Were there any incidents during or soon after this transport that the interviewee can recall when other					

individuals were in contact with a person's blood and/or other body fluids?

-						
-	Did interviewee experience any symptoms (fever, body aches, abdominal pain, diarrhea, rash, sore					
1	throat, severe headache, vomiting, weakness, unusual bruising or bleeding) since the transport with th					
ĺ	index case on board?					
	Yes No (If no, skip to question 6)					
	If yes, which of the following symptoms did the interviewee experience since the flight with the index					
,	case, and what were the onset date and duration of symptoms (check all that apply and list					
,	onset/duration)?					
		Symptom onset (MM/DD/YY)	Duration (in days)			
	Fever ≥100.4° F					
1						
	Sore throat					
	Body aches/muscle pain					
	Severe headache					
	Abdominal pain					
	Vomiting					
	Diarrhea					
1	□					
	Weakness					
	Rash					
	Description of rash					

6.	Has interviewee travelled within the last 21 days to Sierra Leone, Guinea, Liberia, or another country		
	experiencing widespread transmission of Ebola? 🗌 Yes 🗌 No		
	If yes, to which countries did the interviewee travel (check all that apply)?		
	Sierra Leone Guinea Liberia Other		
	If any of the above countries are selected, please notify CDC by calling EOC at 770.488.7100.		
	Interviewee will need to complete additional interview with CDC SME involving in-country exposure risk.		
Cla	assification of interviewee risk. After the HD has completed the interview, CDC will assign a risk level		

and communicate follow up recommendations to the HD. Call the EOC and ask to speak to Air Contact

Investigation Team after the interview to complete this process. Refer to

http://www.cdc.gov/vhf/ebola/exposure/monitoring-and-movement-of-persons-with-exposure.html for additional information.

Follow-up Actions (check all actions taken for this contact):

Active Monitoring: state or local public health authority checks with potentially exposed individual daily to assess for the presence of symptoms and fever (ie: via phone or other communication)

Direct Active Monitoring: public health authority conducts active monitoring through direct observation

Ebola Symptoms (fever, body aches, abdominal pain, diarrhea, rash, sore throat, severe headache,

vomiting, weakness, unusual bruising or bleeding)

Referred for medical evaluation due to presence of symptoms

Where was (s)he referred?		
What was the outcome?		
Was (s)he tested for Ebola?		
Declined medical evaluation after it was recommended		
Placed under conditional release		
Placed under state issued quarantine order		
Controlled movement: exclusion from all long-distance and local public conveyances (aircraft, ship,		
train, bus and subway)		

Exclusion from public places (e.g., shopping centers, movie theaters), and congregate gatherings				
Exclusion from workplaces for the duration of the public health order, unless approved by the state				
or local health department (telework is permitted)				
Federal public health travel restrictions - Do Not Board				
(http://www.cdc.gov/quarantine/q	(http://www.cdc.gov/quarantine/quarantineisolation.html)			
Other, please describe:				
Final Disposition:				
Was interviewee contacted again afte	r the end of the 21-day incubation period?			
Yes, Date of second interview:	/No			
If yes, did interviewee develop any sy	mptoms between the time of the flight and the e	end of the 21-day		
incubation period?	0			
If yes, please specify symptoms, timing, and outcome of medical evaluation below:				
	Symptom onset (MM/DD/YY)	Duration (in days)		
Fever ≥100.4° F				
Sore throat				
Body aches/muscle pain				
Severe headache				
Abdominal pain				
Vomiting				
Diarrhea				
Weakness				
Rash				

Description of rash	
Unusual bruising or bleeding (e.g., from gums, eyes, nose)	
Outcome of medical evaluation:	
Evaluating healthcare provider name/phone number:	/()